allogeneic transplant donor lymphocytes, depleted of tcr-αβ t cells and b cells; enriched for nk cells and tcrγδ t cells
Cell therapyexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jul 4, 2019 (NCT03939585)
Timeline
Indications
Studied for
- Anemia, Aplastic · Phase 2
- Anemia, Diamond-Blackfan · Phase 2
- Anemia, Sickle Cell · Phase 2
- beta-Thalassemia · Phase 2
- Hematopoietic Stem Cell Transplantation · Phase 1
- Hodgkin Disease · Phase 2
- Leukemia, Myeloid, Acute · Phase 2
- Lymphoma, Non-Hodgkin · Phase 2
- Lymphoproliferative Disorders · Phase 1
- Myelodysplastic Syndromes · Phase 1
- Myeloproliferative Disorders · Phase 1
- Neutrophils · Phase 2
Mechanism of action
- Unspecified targetImmunity, passive
Immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04099966 | Phase 2 | Oct 1, 2019 | New York Medical College |
| NCT03939585 | Phase 1 | Jul 4, 2019 | Case Western Reserve University |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Case Western Reserve University | Academic/Hospital | 1 | 1 | 1 | 2019 |
| New York Medical College | Academic/Hospital | 1 | 1 | 1 | 2019 |
2 organizations
Page 1 / 1